Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rang in aandelen #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Aandeelprijs
$1.51
Laatst gesynchroniseerd: 2024-08-26
Marktkapitalisatie
$1.12M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Agile Therapeutics, Inc. (AGRX)

Categorie

Winst voor Agile Therapeutics, Inc. (AGRX)
Winst in Jun 2024 TTM: $-15.86M
Volgens de meest recente financiële verslagen van Agile Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $-15.86M. In 2022 behaalde het bedrijf een winst van $-30.09M, een stijging ten opzichte van de winst van 2021, die $-74.89M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Agile Therapeutics, Inc. van 2012 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-15.86M 9.62%
2023 $-14.47M -51.92%
2022 $-30.09M -59.83%
2021 $-74.89M 44.44%
2020 $-51.85M 178.69%
2019 $-18.61M -8.15%
2018 $-20.26M -28.43%
2017 $-28.30M -11.04%
2016 $-31.82M -12.37%
2015 $-36.31M 84.02%
2014 $-19.73M 37.77%
2013 $-14.32M -38.43%
2012 $-23.26M 0.00%
Winst van vergelijkbare bedrijven of concurrenten